Notice of the 33rd Annual General Meeting of the Company to be held on 29th September, 2025 at 4:00 PM IST through VC/OAVM
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech has notified its 33rd AGM to be held on 29th September 2025 at 4:00 PM via video conferencing, along with the Annual Report for FY 2024-25. The AGM includes adoption of audited standalone and consolidated financial statements and re-appointment of three directors (Muthukrishnan Ramesh, Singarababu Indirakumar, Kasiraman Sayee Sundar) retiring by rotation. Shareholders will vote on rescinding the earlier approved increase in authorized share capital to Rs. 75 Cr (passed at the 32nd AGM but not implemented) and instead approve a new increase to Rs. 85 Cr to facilitate a proposed Rights Issue of Rs. 49.90 Cr. Other items include appointing three directors as Whole-time Directors for 5 years, appointing an Independent Director, approving material related party transactions of up to Rs. 25 Cr each with six subsidiaries for FY 2025-26, re-appointing the Secretarial Auditor for five years, and approving disinvestment from Dindigul Farm Product Limited along with reclassification of IBL's status from 'Promoter' to 'Public' in that subsidiary.
The most significant takeaways for shareholders are the rescinding of the earlier capital hike and replacement with a larger Rs. 85 Cr authorized capital, signalling a Rights Issue of around Rs. 49.90 Cr is on the cards, which could lead to share dilution. The proposed disinvestment of Dindigul Farm Product and reclassification from promoter to public category in that subsidiary suggest strategic restructuring. Multiple related-party transaction approvals with subsidiaries indicate substantial inter-group business activity.